For a long time living modified organisms (LMOs) have been a source of concern and debate by governments, the industrial sector and consumers. As one of the most biologically diverse countries, Peru has not been a stranger to these problems, and the approach of this country has been through the establishment of a moratorium on certain uses of LMOs.
Introduction
On April 15, 2011 the government of Peru published the Supreme Decree No. 003-2011/AG -Biosafety Regulations on Development of Activities with Living Modified Organisms (LMOs) in the Agricultural or Forestry Sector and for Products Derived from LMOs in the Agricultural Sector. This regulation caused a fierce debate among different political parties and the gastronomic and industrial sectors since it was unknown how the entrance of transgenic products to Peru could affect both health and agriculture.
Due to those events, on December 9, 2011, Peru published the Law No. 29811, under which Supreme Decree No. 003-2011/AG was repealed. This Decree imposed a 10-year moratorium on the entry to Peru and production of genetically modified organisms to be released i n to the environment for breeding and cultivation purposes. This law was the result of strong pressure from the Peruvian media and the food sector to protect Peruvian biodiversity, while representatives of the industrial sector defended the use of transgenic seeds.
Therefore, the most important question that deserves a response is: Is this moratorium law consistent with the legal framework on biodiversity protection?
In this regard, we begin this article by describing the Peruvian Legal Framework of Biosafety, then we explain the rules that govern the moratorium, we analyze the arguments that were used to justify the moratorium, a n d later on we explore the moratorium and its relation to the precautionary principle in the CBD and the Cartagena Protocol. The article concludes with a brief review of the moratorium and the possibility that this is a barrier to trade.
I. The Peruvian International Legal Framework of Biosafety
While we recognize that many international instruments address directly or indirectly the issue of biosafety, we will focus on describing two of the most important and relevant to the investigation, the Convention on Biological Diversity and the Cartagena Protocol on Biosafety.
In November 1988, the United Nations Environment Programme (UNEP) convened the Ad Hoc Working Group of Experts on Biological Diversity to explore the need for an international convention on biological diversity. In May 1989, it established the Ad Hoc Working Group of Technical and Legal Experts to prepare an international legal instrument for the conservation and sustainable use of biological diversity. Its work culminated on 22 May 1992 with the Nairobi Conference for the Adoption of the Agreed Text of the Convention on Biological Diversity (CBD). The Convention was opened for signature on 5 June 1992 at the United Nations Conference on Environment and Development (the Rio "Earth Summit"). The Convention entered into force on 29 December 1993, which was 90 days after the 30th ratification 2 .
As can be seen in the objectives of the article 1, the Convention on Biological Diversity (CDB) is an international treaty that promotes the use of natural resources considering conservation, sustainability and equitable sharing of the benefits arising from their use.
"Article 1. Objectives
The objectives of this Convention, to be pursued in accordance with its relevant provisions, are the conservation of biological diversity, the sustainable use of its components and the fair and equitable sharing of the benefits arising out of the utilization of genetic resources, including by appropriate access to genetic resources and by appropriate transfer of relevant technologies, taking into account all rights over those resources and to technologies, and by appropriate funding."
The importance of the Convention on Biological Diversity lies in the identification of probable adverse effects on health and the environment due to modern biotechnology, since it considers, for the first time, the sovereign right of States over their biological resources to exploit these under the regulations of their environmental policies.
"Article 3. Principle
States have, in accordance with the Charter of the United Nations and the principles of international law, the sovereign right to exploit their own resources pursuant to their own environmental policies, and the responsibility to ensure that activities within their jurisdiction or control do not cause damage to the environment of other States or of areas beyond the limits of national jurisdiction."
The Convention defines biological diversity as the variability between living organisms from any sources including, among others, terrestrial, marine and other aquatic ecosystems and the ecological complexes they are part of. Biological diversity also includes variability in and among species and ecosystems. Biological diversity means the variability among living organisms from all sources including, inter alia, terrestrial, marine and other aquatic ecosystems and the ecological complexes of which they are part; this includes diversity within species, between species and of ecosystems (…)"
It should be noted that two important articles of this agreement, because they relate to the research, are Article 6 and Article 10, about general measures for conservation, and the sustainable use of components of Biological Diversity.
"Article 6. General Measures for Conservation and Sustainable Use
Each Contracting Party shall, in accordance with its particular conditions and capabilities:
(a) Develop national strategies, plans or programmes for the conservation and sustainable use of biological diversity or adapt for this purpose existing strategies, plans or programmes which shall reflect, inter alia, the measures set out in this Convention relevant to the Contracting Party concerned; and (b) Integrate, as far as possible and as appropriate, the conservation and sustainable use of biological diversity into relevant sectoral or cross-sectoral plans, programmes and policies". (d) Support local populations to develop and implement remedial action in degraded areas where biological diversity has been reduced; and (e) Encourage cooperation between its governmental authorities and its private sector in developing methods for sustainable use of biological resources." Finally, it is worth mentioning that Signatory Governments to the CBD are required to develop national strategies and action plans based on decisions taken by the Conference of the Parties (COP) and report back on implementation (Peru is a member of the Convention on Biological Diversity since 1993).
B) The Cartagena Protocol on Biosafety
Due to the complexity of modern biotechnology, the CDB stated the need to arrive at a future agreement on biosafety The Cartagena Protocol on Biosafety to the Convention on Biological Diversity is an international treaty governing the movements of living modified organisms (LMOs) resulting from modern biotechnology from one country to another, in other words, it defines the international rules countries will use to trade in these products.
"Article 1. Objective
In accordance with the precautionary approach contained in Principle 15 of the Rio Declaration on Environment and Development, the objective of this Protocol is to contribute to ensuring an adequate level of protection in the field of the safe transfer, handling and use of living modified organisms resulting from modern biotechnology that may have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health, and specifically focusing on transboundary movements".
As can be seen, the Protocol contains reference to a precautionary approach and reaffirms the precaution language in Principle 15 of the Rio Declaration on Environment and Development
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, which we will discuss later. 2. Protocols shall be adopted at a meeting of the Conference of the Parties.
3. The text of any proposed protocol shall be communicated to the Contracting Parties by the Secretariat at least six months before such a meeting." Like most treaties, the CPB establishes general rules as minimum requirements, focusing on transboundary movement of LMOs. The national legislation shall define the development of tools and the abilities to manage LMOs within their territories, as well as the creation of necessary institutional infrastructure. Therefore, the national measures to protect conservation, sustainability and the use of biological diversity may be stricter than the Protocol measures.
"Article 2 General Provisions 1. Each Party shall take necessary and appropriate legal, administrative and other measures to implement its obligations under this Protocol.
2. The Parties shall ensure that the development, handling, transport, use, transfer and release of any living modified organisms are undertaken in a manner that prevents or reduces the risks to biological diversity, taking also into account risks to human health.
3. Nothing in this Protocol shall affect in any way the sovereignty of States over their territorial sea established in accordance with international law, and the sovereign rights and the jurisdiction which States have in their exclusive economic zones and their continental shelves in accordance with international law, and the exercise by ships and aircraft of all States of navigational rights and freedoms as provided for in international law and as reflected in relevant international instruments.
4. Nothing in this Protocol shall be interpreted as restricting the right of a Party to take action that is more protective of the conservation and sustainable use of biological diversity than that called for in this Protocol, provided that such action is consistent with the objective and the provisions of this Protocol and is in accordance with that Party's other obligations under international law.
5. The Parties are encouraged to take into account, as appropriate, available expertise, instruments and work undertaken in international forums with competence in the area of risks to human health."
The CPB sets certain procedures to assess LMOs. It is necessary to create an Advanced Informed Agreement (AIA) and a Risk Assessment before such movement is made since possible risks of LMOs are not defined. The Protocol also contains provisions on Risk Management.
The Advanced Informed Agreement is a previous assessment of the Party of import to determine if a specific level of risk will be assumed from the information previously obtained. The imported product assessment will be made prior to the first transboundary movement of LMOs, and the decision about the product shall be made after a Risk Assessment.
The Risk Assessment establishes possible adverse effects on the conservation and sustainable use of biological diversity and adverse effects on human health, including the possibility of their occurrence and consequences.
"Article 7 Application of the Advance Informed Agreement Procedure 1. Subject to Articles 5 and 6, the advance informed agreement procedure in Articles 8 to 10 and 12 shall apply prior to the first intentional transboundary movement of living modified organisms for intentional introduction into the environment of the Party of import.
(…) 4. The advance informed agreement procedure shall not apply to the intentional transboundary movement of living modified organisms identified in a decision of the Conference of the Parties serving as the meeting of the Parties to this Protocol as being not likely to have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health." "Article 15. Risk Assessment 1. Risk assessments undertaken pursuant to this Protocol shall be carried out in a scientifically sound manner, in accordance with Annex III and taking into account recognized risk assessment techniques. Such risk assessments shall be based, at a minimum, on information provided in accordance with Article 8 and other available scientific evidence in order to identify and evaluate the possible adverse effects of living modified organisms on the conservation and sustainable use of biological diversity, taking also into account risks to human health. 2. The Party of import shall ensure that risk assessments are carried out for decisions taken under Article 10. It may require the exporter to carry out the risk assessment. 2. Measures based on risk assessment shall be imposed to the extent necessary to prevent adverse effects of the living modified organism on the conservation and sustainable use of biological diversity, taking also into account risks to human health, within the territory of the Party of import.
3. Each Party shall take appropriate measures to prevent unintentional transboundary movements of living modified organisms, including such measures as requiring a risk assessment to be carried out prior to the first release of a living modified organism.
4. Without prejudice to paragraph 2 above, each Party shall endeavour to ensure that any living modified organism, whether imported or locally developed, has undergone an appropriate period of observation that is commensurate with its lifecycle or generation time before it is put to its intended use.
Parties shall cooperate with a view to:
(a) Identifying living modified organisms or specific traits of living modified organisms that may have adverse effects on the conservation and sustainable use of biological diversity, taking also into account risks to human health; and (b) Taking appropriate measures regarding the treatment of such living modified organisms or specific traits."
Based on the Advanced Information Agreement and the Risk Assessment, a definite decision will be made on a total or conditioned approval of the LMO importation, or its prohibition. Furthermore, extra information or a longer term may be requested to make a decision.
LMOs are n o t judged equally in the Advanced Informed Agreement and Risk Assessment as it depends on the LMO uses, which may be, according to the CPB:
• Intentional introduction into the environment: the Advanced Informed Agreement shall apply prior to the first transboundary movement.
• Direct use as food or feed or for processing: each Party may make a prior decision regarding specific LMOs.
• Contained use: they are exempted of the AIA, provided that their contained use complies with national regulations.
Finally, the Protocol establishes a Biosafety Clearing-House to facilitate the exchange of information on LMOs and to assist countries in the implementation of the Protocol.
II. The Peruvian National Legal Framework of Biosafety
Contrary to what some may think, Peru has had a biosafety regimen for many years; however, we acknowledge its implementation and development have not been very successful.
A These national rules regulate activities including research, production, introduction, handling, transport, storage, conservation, interchange, commercialization, contained use, and release of LMOs under controlled conditions. Furthermore, these regulations define the Organismos Competentes Sectoriales -OSC (Competent Sector Agencies) in our country. These agencies are in charge of elaborating sector regulations to establish mechanisms and procedures for LMO treatment in their applicable sectors: Note that Law 27104 and its Regulations set the characteristics the risk assessment shall have: it must follow the AIA's procedures; the analysis of each case must be made separately and be based on information provided by the requestor, and the assessment shall be based on the precautionary principle.
This Law and its Regulation also point out that when the use of an LMO has been regulated or rejected by the competent authorities in a country, the request will be flatly denied, that is, its utilization will be prohibited within our country. LMOs that have not been a pproved in a different country will not be admitted because their use may imply a risk.
However, contrary to Cartagena Protocol's provisions, procedure differences for the end uses of LMOs have not been established. The Supreme Decree caused a broad reaction in the media, since it was seen as a mechanism of LMO free entrance to our country. After a long debate in the Congress, said Decree was repealed by Law 29811, which sets a moratorium of ten years on releasing LMOs into the environment for cultivation or breeding purposes.
Is it true that this Decree allowed LMOs to enter our country without any measures, assessment, or technical procedures? Even though the said Decree was not perfect, limitations set by Law 27104 regarding rejected, regulated or not proven LMOs in other countries prevented the free entry of these products into our country. This limitation stated that the applicant shall notify any application for the use of an LMO submitted abroad as well as the stage of said application or applications, specifying if they are in process or have been regulated or rejected.
Without prejudice to the foregoing, note that the repealed Supreme Decree 003-2011/AG did not include agricultural diversification and source areas that are currently considered in Law 29811; neither did it specify the validity period of registries of genetically modified products.
III. Provisions of Law 29811 and its Regulation on the Moratorium
This Law aims at national capacity improvement, infrastructure development and generating baselines for native biodiversity to allow an appropriate assessment of LMO release activities on the environment. It should be noted that, as per these Regulations, an LMO is any living organism having a new combination of genetic material obtained from the use of modern biotechnology 6 .
Additionally, the Regulation e s tab lis he d that the baselines are systematized and analyzed information showing the current situation of native biodiversity (including genetic biodiversity of native species) that may be affected by LMOs and their use. The baseline generated will consider native species as a priority, then naturalized species and, finally, new alien species or those recently introduced.
The Law sets o u t that the minimum information contained in the baselines shall consist in lists and distribution maps of: In light of this, what the Law 29811 specifically states is that Living Modified Organisms (LMOs) cannot enter Peru or be produced for agricultural 7 or breeding 8 purposes for 10 years so they cannot be released into the environment. Under the Regulations of this Law, releasing into the environment means an intentional or accidental introduction of an LMO to an external environment.
The law states that the following are excluded from the moratorium:
• LMOs for research purposes, provided that they are used in contained spaces such as buildings or facilities where LMOs are handled and controlled by specific measures that effectively limit their contact with the environment and their impact on the medium.
• LMOs used as pharmaceuticals or veterinary products subject to International Treaties of which Peru is part and to special laws.
• LMOs or their imported by-products intended for direct use as food or feed or for processing.
Living Modified Organisms excluded from this moratorium shall be subject to risk analyses previous to use authorization and the application of measures for risk assessment, management, and communication. Note that, under no circumstances c a n the authorized use be replaced by agricultural or breeding use.
All genetic material entering the national territory, except that included in the exceptions to the moratorium, shall provide evidence that it is not an LMO. If the analyzed material turns out to be an LMO, the competent authority shall seize and destroy such material and impose applicable sanctions (fines).
One of the main authorities is the Ministerio del Ambiente (Ministry of the Environment) 9 according to Law 29811, which is responsible for capacity building to fulfill the biosafety requirements and the mechanisms for protecting and promoting native biodiversity. I n p articular, it is in charge of generating baselines about biodiversity potentially affected by the LMO release as well as determining the environmental land use planning to ensure the preservation of biodiversity.
Finally, the Ministry is also responsible for overseeing and implementing centers of origin and diversification and, in coordination with the Consejo Nacional de Ciencia, Tecnología e Innovación Tecnológica -Concytec (National Council for Science, Technology, and Technological Innovation) 10 , is responsible for promoting capacity-building in science and technology at the national institutions in charge of disseminating the techniques used by modern biotechnology and biosafety in view of contributing to the suppliers' and consumers' decision-making with regard to LMOs, and promoting biotechnology based on native genetic resources to achieve its conservation and competitive development. According to the Regulations, center of origin means the geographical area where a c u l t i v a t e d or wild species obtains its first distinctive characteristics and shares its distribution range with other closely related species. Center of diversification is also mentioned; this is a geographical area with great in situ genetic diversity (intraspecific and interspecific diversity).
To comply with the aims of Law 29811, the Regulations have set the creation of several Special Programs and Projects, specifically: potentially affected by LMOs and their use. This way, an appropriate risk assessment will be ensured in each case when the moratorium period expires.
• Program for Biotechnology and Competitive Development: This promotes biotechnology based on native genetic resources in order to achieve their conservation and competitive development in financial, social, and scientific aspects. It identifies biotechnology applications on a multisectoral level and assesses their appropriateness and ability to resolve particular issues in national productive processes or in service creation.
• Special Project for the Development of Technological and Scientific Abilities used in Modern Biotechnology regarding Biosafety: This promotes the development of technological and scientific abilities of national institutions. It provides technical/scientific training to develop human abilities regarding research, biotechnological improvement, and innovation.
IV. The arguments in Peru to justify the moratorium
In general, the following benefits and concerns are usually indicated by the specialist for Genetically Modified Organisms (GMO).
Benefits
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:
Crop improvement: for example, improved resistance to disease and reduced maturation time.
Animal improvement: for example, accelerated growth and disease resistance.
To the Environment: for example, GMOs need less pesticide, and may help in the conservation of soil and water.
To Society: for example, GMOs may help to produce more food for growing populations. Health safety: for example, the impact of GMOs on allergies and antibiotic resistance.
Concerns
Potential environmental impacts: for example, the loss of flora and fauna biodiversity.
Intellectual Property issues: for example, the risk of having world food production dominated by a few companies and biopiracy.
Ethics: interfering with nature by mixing genes among species can be seen as an ethical dilemma because it violates the natural development of organisms.
Labeling: There is a controversy regarding the need to label GMO products. On the one hand, it is argued that it is necessary to respect the consumer's right to be informed and to choose but, on the other hand, t h e r e is the position that states that while products are not harmful, there is no need to label, as this can unjustifiably affect consumption.
In Peru, after the Supreme Decree 003-2011/AG enacting, many politicians and gastronomic sector representatives spoke against the entrance of LMOs into Peru. This led to the Law being repealed and the enacting of Law 29811 which set the moratorium. The main arguments presented are summarized as follows:
• Biodiversity: The recent country brand advertises Peru as a country offering different and unique experiences not found in other countries. Biodiversity is one of the aspects that make the country unique and it may be affected by the entrance of LMOs 19 .
• Productivity: Due to the great Peruvian biodiversity, LMOs are not necessary to improve the country's productivity. More organic crops 20 shall be produced instead 21 .
• Risk to environment: When the transgenic material is in the field, sooner or later it will be transported to other close species and crops by means of 19 These and similar declarations were made by several chefs, Gaston Acurio being one of them. Were these arguments supported or were they just based on irrational fears and political interests? Biodiversity: If biological diversity is the variability in genes, species, and ecosystems, as well as all ecologic processes necessary for all forms of life, then it is correct to say that Peru has a wide biological diversity, even though there is no detailed information about it.
As stated in our National Strategy on Biological Diversity 23 , Peru has 84 life zones and 17 transitional zones of 104 in the world, 8 biogeographic provinces and 3 big river basins. It has a great variety of flora, approximately 25000 species (10% of the planet's total), where 30% are endemic. It is the fifth country in number of species; it is the first in number of plant species with known properties and used by population (4400 species) and also the first in the number of native cultivated species (128 species).
With regard to fauna, Peru is in the first place in varieties of fish (10% of the planet's total), the second in birds (1736 species), the third in amphibians (332 species), the third in mammals (460 species), and the fifth in reptiles (365 species). Also, it is one of the most important countries with endemic species with, at least, 6288 (5528 of flora and 760 of fauna).
It has a wide genetic diversity: it has the first place in varieties of potatoes (150 wild species), chili, corn (36 species), Andean grains, tubers, and Andean roots. It has 4400 species of native plants with known uses, mainly those with nutritional (782), medical (1300), and ornamental properties (1600).
It has five domestic forms: alpaca, domestic form of vicuña (Lama vicugna); llama, domestic form of guanaco (Lama guanicoe); cuy, domestic form of poronccoy (Cavia tschudii), Criollo duck, domestic form of Amazon duck (Cairina moschata), and cochinilla (dactilopius coccus).
In financial terms, Peruvian biological diversity is the basis of the national economy: 99% of fisheries depend on hydrobiological resources, at least 65% of agricultural production is based on native genetic resources, 95% of livestock consumes native natural grasses, and 99% of forest industry consumes forests and native species. Furthermore, our country promotes a country brand that aims at making our diversity known, including biodiversity ("There is a Peru for each and everyone") 24 .
One of the problems is that our biodiversity is still quite unknown in our country. For example, only recently, thanks to the joint efforts of a Peruvian-Canadian cooperation project, was it possible to identify 509 varieties of native potatoes 25 .
As can be deduced, without knowing our biodiversity well it is very difficult to determine which products (genetically modified or not) might be liable to affect it.
The second problem, related to the first, is that all LMOs do not have the same effects, therefore, it is possible that a specific LMO does have an impact on some element of our biodiversity but, at the same time, another LMO is completely harmless.
Productivity: Stating that it is not necessary to increase our productivity via LMOs due to our great diversity is really difficult to confirm, because we do not know the maximum benefits of our biodiversity exploitation in the future. Added to this, there is little current and available information about organic production in Peru.
Notwithstanding the foregoing, some data shows the following:
• The most important products with Organic Certification in Peru are: coffee, cotton, cotton fiber and textiles; fresh vegetables and fruits, such as mango, banana, grapes and papaya; native and exotic fruit; Andean tubers and grains like quinoa, amaranth, yacon and maca; sesame; olives and olive oil; palm, citrus aurantifolia, tomatoes and tomato paste, Brazil nuts, honey, essential oils, a wide range of natural colorants and different herbs with aromatic and medicinal use 26 .
• • Peru is one of the leading exporting countries of organic products in Latin America and globally it ranks around fifth, generally behind China, Brazil and Chile
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One big problem is that 81% of agricultural land in the country, especially in the highlands, is less than five hectares i n s i z e and that l i m i t s the competitiveness of small producers to, for example, address demand for quinoa (the Andean countries produce no more than 100,000 tonnes annually) 29 .
Although Peru is positioning i t se lf slowly in organic production, we have not found any scientific study dedicated to examining the possibility of relying solely on these crops for domestic consumption and exportation.
Risk to environment: It is true that wind and insects may transport transgenic material to an area where that material is not wanted. The fear of this crop contamination tends to focus on the possibility of the modified seed becoming an uncontrollable weed.
In this respect, although each situation must be taken independently, the case of herbicide tolerant canola in Canada can be taken as an example. In this case, although one of the initial concerns was an uncontrollable development of herbicide tolerant canola, according to a 2010 study, most surveys dismissed this concern as 62% reported no difference in controlling for volunteer GM canola than for regular canola, and only 8% indicated that they viewed volunteer GM canola to be one of the top five weeds they need to control In addition, a moratorium in our country would not necessarily prevent contamination of crops. We cannot ignore that several neighboring countries (for example, Argentina and Brazil) have allowed, in some way, the entrance or production of LMOs within their national boundaries. This way, LMOs from these countries may enter into ours, even if they are prohibited in Peru.
In conclusion, although the reasons given to justify the moratorium were not unreasonable, they were based on intuition, as there is little information about our biodiversity, organic production and environmental effects of introducing LMOs.
V. The moratorium and the precautionary principle in the CBD and Cartagena Protocol
A) The precautionary principle "In order to protect the environment, the precautionary approach shall be widely applied by States according to their capabilities. Where there are threats of serious or irreversible damage, lack of full scientific certainty shall not be used as a reason for postponing cost-effective measures to prevent environmental degradation."
The analysis of the precautionary principle involves a great challenge. Not only because of the lack of uniformity in its application, but also by the different ways of understanding it. Even in identifying its key elements, the doctrine is not uniform 31 . Nevertheless, in an attempt to point out its elements simply, we have 32 : a) the threat of harm, b) the lack of scientific evidence and, c) the need and duty to act. , some formulations of this principle require that the injury is severe and irreversible (as in The Rio Declaration). On the other hand, the Cartagena Protocol requires "imminent harm" and "adverse effects" to trigger this principle.
ii. Uncertainty
The Rio Declaration refers to "lack of full scientific certainty" and many definitions in other international instruments are vague about how much certainty must be demonstrated regarding a product or activity's safety In general, uncertainty may refer to situations in which there is no strong evidence of safety or benefits of the product or the activity. It also refers to evidence t h a t i s incomplete or not available 35 .
iii. Necessity and duty to act There is no consensus on which measure is applicable for each activity, but there are a variety of possible actions that could be taken to deal with possible harmful effects. These include: doing nothing; merely considering action; performing further research to improve understanding; in the case of a product, performing pre- market testing; warning people of the possible harm caused by the product or activity (in the case of products, this could include labelling); monitoring the product or activity to look for evidence of possible harm; taking measures to reduce the impact of the possible harm (for example, by preventing exposure to it); placing strict regulations on the product or activity; placing a moratorium on the product or activity; phasing out the product or activity; and placing an outright ban on the product or activity 36 .
B) In the Convention on Biological Diversity (CBD)
Like other environmental agreements, the CBD contains the "precautionary approach" but it doesn't mention precaution by name. In this regard, the preamble of the Convention states that "where there is a threat of significant reduction or loss of biological diversity, lack of full scientific certainty should not be used a s a reason for postponing measures to avoid or minimize such a threat". This version of the precautionary principle is similar to the statements in the Rio Declaration.
C) In the Cartagena Protocol
This instrument also contains a "precautionary approach" in the preamble: "reaffirming the precautionary approach contained in Principle 15 of the Rio Declaration on Environment and Development".
The Protocol also reflects precautionary decision-making in Article 1 (Objective), in Articles 10 (Decision procedure) and 11 (Procedure for living modified organisms intended for direct use as food, feed, or for processing), and in Annex III paragraph 4 (Risk assessment) "Article 10. Decision Procedure (…) 6. Lack of scientific certainty due to insufficient relevant scientific information and knowledge regarding the extent of the potential adverse effects of a living modified organism on the conservation and sustainable use of biological diversity in the Party of import, taking also into account risks to human health, shall not prevent that Party from taking a decision, as appropriate, with regard to the import of the living modified organism in question as referred to in paragraph 3 above, in order to avoid or minimize such potential adverse effects." 
8.Lack of scientific certainty due to insufficient relevant scientific information and knowledge regarding the extent of the potential adverse effects of a living modified organism on the conservation and sustainable use of biological diversity in the Party of import, taking also into account risks to human health, shall not prevent that Party from taking a decision, as appropriate, with regard to the import of that living modified organism intended for direct use as food or feed, or for processing, in order to avoid or minimize such potential adverse effects."
4. Lack of scientific knowledge or scientific consensus should not necessarily be interpreted as indicating a particular level of risk, an absence of risk, or an acceptable risk."
During the negotiations of this Protocol the use of the wording "precautionary principle" was blocked by the US and some other governments. The dispute was based on the fact that the precautionary principle is not yet recognized as an internationally recognized principle of law. The US and supporting governments did not want the Biosafety Protocol negotiations to set a precedent and recognize the Precautionary Principle as a principle 37 .
D) The establishment of a moratorium and the precautionary principle
Applying the key elements that we have identified to the establishment of a moratorium, we believe that:
 Regarding the Threat of Harm:
Due to the complexity and still lack of certainty about the effects of GMOs on human health and biodiversity, these organisms are candidates for the application of this principle. 38 Thus, at least potentially, the effects of these products could be severe and irreversible The level of uncertainty is in dispute because "current knowledge is not sufficient to be able to draw scientifically (...) trusted conclusions about potential environmental effects of transgenic animals or their safe and effective management" 40 . In this regard, science "has not fully responded to concerns about long-term environmental impacts and possible spillover effects to wild plant varieties". 41 Added to the above, also because of the complexity of ecosystems, costs and the difficulty in monitoring GMOs (that could take years to show its effects) 42 it is possible to say that GMOs comply with this element.
 Regarding the necessity and duty to act
Although there is no consensus on which measure is applicable for each activity 43 , the precautionary GMO regulation requires that governments act t o reverse the burden of proof on proponents of an activity to demonstrate that GM will not have negative effects on human health or the environment 44 . Another measure proposed includes monetary deposits in advance of any activity that may endanger the environment, environmental impacts 45 and the development of a system of liability and compensation as is proposed in article 27 of the Cartagena Protocol.
We consider that it is appropriate to establish a moratorium to assess the effects on our biodiversity of LMOs released into the environment. Because every environment has a unique ecosystem, which implies that biosafety studies are difficult to generalize, we think that biosafety standards for health and environmental impact may require specific testing for the environment where the LMO will be introduced 46 .
For this reason, even though the Cartagena Protocol does not include the establishment of a moratorium to protect biodiversity, its Article 2 does allow stricter measures, provided that they are not opposed to the objectives and provisions of the Protocol. We believe that by itself, the existence of a moratorium does not violate the Cartagena Protocol; since the Protocol itself allows stricter measures, and, from our point of view, a temporary measure, such as a moratorium, would be stricter than an assessment of each case 47 48
VI. A different problem: the perspective of commerce.
Norms of precaution present particular difficulties because in a trade agreement dispute settlement proceeding they appear to be pretexts for protectionism. Thus, even considering that the moratorium, by itself, does not violate the Cartagena Protocol, there may be problems in relation to trade, which we will mention briefly. . Therefore, the agreement governs both food safety measures and agricultural quarantines. The WTO SPS Agreement has a different purpose from the CBD and the Cartagena Protocol because it is not an environmental agreement; its objective is not to protect the environment or biodiversity but to reduce trade barriers and to eliminate discriminatory treatment in international trade 50 .
The core of the SPS text is a series of science-based disciplines. An SPS measure that is not based on international standards must be supported by "a scientific justification" (Article 3.3). A challenged measure must be "based on scientific principles" (Article 2.2), must not be "maintained without sufficient scientific evidence" (Article 2.2), and the regulatory process leading to the measure must "take into account available scientific evidence" (Article 5.2). A central feature of the SPS Agreement, found in Article 5.1, is a requirement for a risk assessment, and the principal operative test in the agreement is the need for the measure to be "based on" that risk assessment. The SPS Agreement consequently codifies requirements for an approach to regulation roughly commensurate with the risk assessment/risk management duality.
51
Even though the word "precaution" does not appear in the text of the SPS Agreement, Article 5.7 of the SPS Agreement incorporates policies similar to those underlying precautionary approaches:
49 Preamble:
"Reaffirming that no Member should be prevented from adopting or enforcing measures necessary to protect human, animal or plant life or health, subject to the requirement that these measures are not applied in a manner which would constitute a means of arbitrary or unjustifiable discrimination between Members where the same conditions prevail or a disguised restriction on international trade.
(…) Related to this, it is important to note that the Cartagena Protocol says little regarding its interpretation alongside other international trade agreements, including those under the WTO (the preamble states that the protocol is to be mutually supportive, not subordinate to other international agreements) 52 .
For a better understanding of the relation between the precautionary approach and de SPS agreement, especially in the context of a moratorium, it is worth mentioning the EC -Biotech case.
The EC-Measures Affecting the Approval and Marketing of Biotech Products dispute (EC--Biotech): in this case, the US, Canada, and Argentina accused the EU of having imposed a de facto moratorium on the commercialization of GMOs, maintained between 1999 and 2003 by "undue delay" in the approval procedure (the EC scheme required prior governmental authorization before a GMO may be placed on the market.). The complainants claimed that the European Member States either never performed the risk assessments on GMOs or dismissed the positive results of risk assessments. Thus, according to the complainants, the European behavior violated Article 5.1 of the SPS Agreement, which requires that SPS measures be based on scientific risk assessment. In the absence of such an assessment, the European delay amounted to a non-necessary and nonscience-based restrictive measure to trade 53 .
The European Communities argued that the safeguard measures on the import of certain GMOs were adopted by six EC member states (Austria, France, Germany, Greece, Italy, and Luxembourg) but, the case of inconsistency was to be examined under Article 5.7 of the SPS Agreement instead of Article 5.1, the former contemplating the case of insufficient scientific evidence and better reflecting the precautionary principle 54 The WTO Dispute Settlement Body issued its ruling on the complaints, on the one hand faulting the EC for "undue delay" in approving GMO products for a four-year period ending in 2003 and, on the other, accusing a number of EC member states of maintaining unjustified bans on genetically modified products already found safe by the European scientific committees. Indeed, the justification of the six European states that scientific results were not "convincing" and needed further evaluation before they would allow the import of these products was not upheld by the Panel, which found no GMO case where scientific evidence was insufficient to perform an adequate risk assessment 55 . In other words, the Panel concluded that the EC member state safeguard measures violated the SPS Agreement because they were not based on risk assessments and hence could be presumed to be maintained without sufficient scientific evidence.
It is important to mention that the United States has signed but not ratified the Biodiversity Convention, and Argentina and Canada have signed the Biosafety Protocol but not yet ratified it. Therefore, none were parties of these agreements which were inapplicable to the dispute.
b) The Peruvian moratorium: its duration and implementation While the moratorium may not be a violation of the CBD and the Cartagena Protocol, there is reasonable concern regarding the possibility of trading being affected with this measure 56 .
There are certain aspects which could indicate that this measure is a barrier to trade:
The duration After reviewing the general provisions of the Law 29811 and the bills prior to this norm 57 , we can see that no one had a clear idea of how long the moratorium period should be, as some bills suggested three years, and others proposed 10 or 15 years. Worse, i n none of the bills, nor in the general provisions, w a s scientific analysis conducted to determine how long the moratorium needed to be in order to meet 55 Ibid. 56 Notwithstanding the above, there are some elements of the moratorium law that allow it to be considered as not posing an obstacle to trading: • The moratorium applies to both importations and national development; therefore, there is no intention to support the national industry.
• The moratorium does not apply either to the importation of inputs or food and/or feed, or for searching or pharmaceuticals production purposes, since a very wide restriction on LMOs could be considered as a hidden restriction to trading.
• Transgenic by-products may be imported, provided that they will not be released into the environment for agricultural or breeding purposes. their goals. In fact, the Law was almost subject to Executive Power regulation due to, among other reasons, concern about the moratorium period being too long 58 .
It is very bad that the moratorium period was established without scientific analysis, because it means we do not have good arguments to defend ourselves if our country is denounced for acts that create barriers to trade.
The implementation  The baselines: There is a reasonable concern regarding the possibility of trading being affected with this measure, since the way provisions of Law 29811 will be applied is uncertain. For example, it is unknown what the specific content of the baselines will be and if they will be considered as an excuse to reject any LMO when the 10-year term ends 59 .
 The progress of the implementation: One of the problems we may face, even if the moratorium itself and its period are considered legal, is its slow and deficient implementation.
In general, the Peruvian government is usually slow in implementing the rules, especially those involving research 60 and major changes 61 . 58 the sampling of imported seeds to detect LMOs nor the Guide to the qualitative detection of LMOs (there are only bills on these topics) 66 .
• The Committee Technical Standards on Biosafety of LMO has generated some technical standards on methods of analysis for the detection of GMOs and derived products, as well as technical standards for LMOs and their biosafety 67 .
• The following is still under development
68
: The Multi-sectoral Plan for monitoring and early warning detection of LMO in the fields; the Guide on sampling and qualitative detection of transgenic ornamental fish; the Guide on sampling and detection of LMOs in crop fields; studies for the baseline of native species to understand the diversity of species, varieties and breeds that have commercial transgenic events (first studies are on corn, cotton, potato and tomato).
There are several explanations of why the implementation is delayed Second, there are problems of coordination between the agencies responsible, because some of them do not accord the issue the necessary priority. This is reflected in the fact that some entities do not include, in their annual budget, a separate line item for financing actions related to the implementation. Also, the restructuring of the Ministry of Agriculture and the National Fish Health Service have made more difficult the implementation of the regulation that applies to them.
Finally, it appears that the Multi-sectoral Advisory Commission does not have a strong role yet.
